Kazunori Yoshikawa
Vorstandsvorsitzender bei Veneno Technologies Co. Ltd.
Profil
Kazunori Yoshikawa is the founder of AQUA Therapeutics Co., Ltd.
which was founded in 2012.
He is currently the President & Chief Executive Officer of Veneno Technologies Co. Ltd.
Mr. Yoshikawa's former positions include Director & EVP-Business Administration at M's Science Corp., Director at BONAC Corp., and Principal at Chugai Pharmaceutical Co., Ltd.
Mr. Yoshikawa received his undergraduate degree from Tohoku University in 1990.
Aktive Positionen von Kazunori Yoshikawa
| Unternehmen | Position | Beginn |
|---|---|---|
Veneno Technologies Co. Ltd.
 Veneno Technologies Co. Ltd. BiotechnologyHealth Technology Veneno Technologies Co. Ltd. is a Japanese company that researches and develops therapeutic disulfide-rich peptides. The company is based in Tsukuba, Japan. The company was founded in 2020. The CEO is Kazunori Yoshikawa. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Kazunori Yoshikawa
| Unternehmen | Position | Ende |
|---|---|---|
BONAC Corp.
 BONAC Corp. Medical SpecialtiesHealth Technology BONAC Corp. develops diagnostic drugs based on nucleic acid chemistry. The company was founded in February 2010 and is headquartered in Kurume, Japan. | Direktor/Vorstandsmitglied | - |
AQUA Therapeutics Co., Ltd.
 AQUA Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology AQUA Therapeutics Co., Ltd. develops therapeutic drugs focused on the treatment of ophthalmological diseases. It uses a nucleic acid interference platform aimed at gene targets of select diseases. The firm's technologies include diabetic retinopathy, Periostin, and Bonac nucleic acid. It also offers research, development, manufacture, and marketing of other pharmaceuticals; non-medicinal products and cosmetics; and medical devices, instruments, and equipment. The firm also conducts medical research and consulting services. The company was founded by Kazunori Yoshikawa on March 19, 2012 and is headquartered in Kobe, Japan. | Gründer | - |
| CHUGAI PHARMACEUTICAL CO., LTD | Corporate Officer/Principal | - |
M's Science Corp.
 M's Science Corp. Miscellaneous Commercial ServicesCommercial Services M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan. | Verwaltungsdirektor | - |
Ausbildung von Kazunori Yoshikawa
| Tohoku University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CHUGAI PHARMACEUTICAL CO., LTD | Health Technology |
| Private Unternehmen | 4 |
|---|---|
M's Science Corp.
M's Science Corp. Miscellaneous Commercial ServicesCommercial Services M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan. | Commercial Services |
AQUA Therapeutics Co., Ltd.
AQUA Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology AQUA Therapeutics Co., Ltd. develops therapeutic drugs focused on the treatment of ophthalmological diseases. It uses a nucleic acid interference platform aimed at gene targets of select diseases. The firm's technologies include diabetic retinopathy, Periostin, and Bonac nucleic acid. It also offers research, development, manufacture, and marketing of other pharmaceuticals; non-medicinal products and cosmetics; and medical devices, instruments, and equipment. The firm also conducts medical research and consulting services. The company was founded by Kazunori Yoshikawa on March 19, 2012 and is headquartered in Kobe, Japan. | Health Technology |
BONAC Corp.
BONAC Corp. Medical SpecialtiesHealth Technology BONAC Corp. develops diagnostic drugs based on nucleic acid chemistry. The company was founded in February 2010 and is headquartered in Kurume, Japan. | Health Technology |
Veneno Technologies Co. Ltd.
Veneno Technologies Co. Ltd. BiotechnologyHealth Technology Veneno Technologies Co. Ltd. is a Japanese company that researches and develops therapeutic disulfide-rich peptides. The company is based in Tsukuba, Japan. The company was founded in 2020. The CEO is Kazunori Yoshikawa. | Health Technology |